| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
62,030,000 |
| Market
Cap: |
73.82(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.06 - $5.55 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MacroGenics is a biopharmaceutical company. Co.'s main pipeline program is MGC018, an antibody-drug conjugate that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Co. is also developing enoblituzumab, an Fc-optimized monoclonal antibody that targets B7-H3 and molecules that target programmed cell death protein 1, a protein that is important in the regulation of the immune system's response to cancer. In addition, Co. is developing MGD024, a bispecific DART molecule that engages CD3 on immune effector cells to kill CD123-expressing cancer cells in certain hematological malignancies, including acute myeloid leukemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
350,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,722,425 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
423 |
423 |
293,823 |
| Total Sell Value |
$0 |
$1,083 |
$1,083 |
$4,996,321 |
| Total People Sold |
0 |
1 |
1 |
6 |
| Total Sell Transactions |
0 |
1 |
1 |
12 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chhabra Meenu |
Director |
– • – |
2025-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
11,000 |
|
- |
|
| Obrien Federica F. |
Director |
– • – |
2025-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
11,000 |
|
- |
|
| Ferrante Karen Jean |
Director |
– • – |
2025-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
11,000 |
|
- |
|
| Stump David C |
Director |
– • – |
2025-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
11,000 |
|
- |
|
| Liu Margaret |
Director |
– • – |
2025-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
11,000 |
|
- |
|
| Siegel Jay Philip |
Director |
– • – |
2025-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
11,000 |
|
- |
|
| Jackson Scott Thomas |
Director |
– • – |
2025-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
11,000 |
|
- |
|
| Heiden William K |
Director |
– • – |
2025-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
11,000 |
|
- |
|
| Hurwitz Edward |
Director |
– • – |
2025-05-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,500 |
44,074 |
|
- |
|
| Spitznagel Thomas |
Sr VP, Technical Ops |
• – – |
2025-02-15 |
4 |
D |
$2.56 |
$14,131 |
D/D |
(5,520) |
21,402 |
|
- |
|
| Spitznagel Thomas |
Sr VP, Technical Ops |
• – – |
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,332 |
26,922 |
|
- |
|
| Eck Stephen L. |
Chief Medical Officer |
• – – |
2025-02-15 |
4 |
D |
$2.56 |
$12,652 |
D/D |
(4,942) |
29,377 |
|
- |
|
| Eck Stephen L. |
Chief Medical Officer |
• – – |
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,665 |
34,319 |
|
- |
|
| Karrels James |
SVP, CFO and Secretary |
• – – |
2025-02-15 |
4 |
D |
$2.56 |
$14,822 |
D/D |
(5,790) |
186,801 |
|
- |
|
| Karrels James |
SVP, CFO and Secretary |
• – – |
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,998 |
192,591 |
|
- |
|
| Koenig Scott |
President and CEO |
• • – |
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
42,329 |
777,415 |
|
- |
|
| Peters Jeffrey Stuart |
Senior VP and General Counsel |
• – – |
2025-02-15 |
4 |
D |
$2.56 |
$13,176 |
D/D |
(5,147) |
13,711 |
|
- |
|
| Peters Jeffrey Stuart |
Senior VP and General Counsel |
• – – |
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,332 |
18,858 |
|
- |
|
| Smith Beth Ann |
VP, Controller & Treasurer |
• – – |
2025-02-15 |
4 |
S |
$2.56 |
$1,083 |
D/D |
(423) |
9,532 |
|
56% |
|
| Smith Beth Ann |
VP, Controller & Treasurer |
• – – |
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,095 |
9,955 |
|
- |
|
| Risser Eric Blasius |
Chief Operating Officer |
• – – |
2025-02-15 |
4 |
D |
$2.56 |
$16,468 |
D/D |
(6,433) |
55,989 |
|
- |
|
| Risser Eric Blasius |
Chief Operating Officer |
• – – |
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,665 |
62,422 |
|
- |
|
| Bonvini Ezio |
Sr VP, Research & CSO |
• – – |
2025-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,665 |
124,414 |
|
- |
|
| Smith Beth Ann |
VP, Controller & Treasurer |
• – – |
2025-02-08 |
4 |
D |
$2.60 |
$1,591 |
D/D |
(612) |
8,860 |
|
- |
|
| Smith Beth Ann |
VP, Controller & Treasurer |
• – – |
2025-02-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,583 |
9,472 |
|
- |
|
283 Records found
|
|
Page 1 of 12 |
|
|
0.08 (6.3%) 
